UCLA researchers find new method for measuring treatment of rare liver disease in children

February 19, 2020

UCLA researchers who previously found that intravenous administration of fish oil can treat a rare but potentially deadly form of liver disease in children have now monitored levels of a small molecule at the center of the disorder to track treatment results. In a new study, they also have identified the way specific genes change after fish oil treatment is started.

"Our study sheds light on some of the mechanisms by which IV fish oil helps treat this disease. It also suggests that measuring levels of the molecule might someday be used to diagnose and monitor this and other liver diseases without the need for biopsies," said Dr. Kara L. Calkins, first author of a study published in the Journal of Nutrition. She participated in the study with colleagues at the Neonatal Research Center of the UCLA Children's Discovery and Innovation Institute, the David Geffen School of Medicine at UCLA, and UCLA Mattel Children's Hospital.

When the liver suffers damage, the small molecule, micro-RNA 122, or miR-122, is released into the bloodstream. The researchers said this is the first study to measure miR-122 in children with intestinal failure-associated liver disease, or IFALD. Risk factors for the disease include prematurity, sepsis, and altered intestinal permeability, a digestive condition in which bacteria and toxins are able to "leak" through the intestinal wall.

The study involved 14 children ages 3 months to 5 years old who were successfully treated with pure fish oil administered intravenously. Blood samples were collected at various times throughout the study to measure the level of the molecule in their bodies. Calkins said larger clinical trials will be needed to confirm results.

"Liver disease is a major health problem that can result in liver failure, the need for a liver transplant or even death," said Dr. Sherin Devaskar, lead author of the study and physician-in-chief of UCLA Mattel Children's Hospital and professor of pediatrics at the David Geffen School of Medicine. Because laboratory tests are not always accurate in predicting or diagnosing the disease, liver biopsy is the current standard treatment.

"One of our research goals is to find inexpensive, practical and accurate tests that predict and diagnose liver disease and provide an accurate measure of treatment response," Devaskar said. "This study suggests that plasma miR-122 may serve as a noninvasive marker of liver disease in children with IFALD, and we believe it could be an important surrogate for other liver diseases.''
-end-
In addition to Calkins and Devaskar, other authors on the study included Shanthie Thamotharan, staff research associate at UCLA, Shubamoy Ghosh, PhD, assistant project scientist in the department of Pediatrics-Neonatology at UCLA, and Yun Dai, MD, PhD, who was a project scientist in the Pediatrics-Neonatology department at UCLA during the time of the study.

Funding was provided from the National Institutes of Health and the UCLA Clinical and Translational Science Institute.

Disclosures: Calkins has received research support from Fresenius Kabi and is a consultant for Fresenius Kabi, the company that manufactures the fish oil used in the study. Fresenius Kabi was not directly involved in this study. The other authors report no conflicts of interest.

University of California - Los Angeles Health Sciences

Related Liver Disease Articles from Brightsurf:

Fatty liver disease despite a normal weight
Researchers from the University of Tsukuba found significant differences in the clinical presentation of non-obese patients with non-alcoholic fatty liver disease (NAFLD) based on their sex and body mass index.

Sobering reminder about liver disease
Alcohol's popularity and its central place in socialising in Australia obscures the dangers of excessive drinking and possible liver disease, Flinders University experts warn.

Giant leap in diagnosing liver disease
A collaborative team of Salk Institute and UC San Diego scientists have created a novel microbiome-based diagnostic tool that, with the accuracy of the best physicians, quickly and inexpensively identifies liver fibrosis and cirrhosis over 90 percent of the time in human patients.

Link between liver and heart disease could lead to new therapeutics
A newly published study of flies found that protecting liver function also preserves heart health.

Fatty liver disease is underdiagnosed in the US
According to an analysis published in Alimentary Pharmacology & Therapeutics, nonalcoholic fatty liver disease (NAFLD) is grossly underdiagnosed in the United States.

Possible new treatment strategy for fatty liver disease
Researchers at Karolinska Institutet in Sweden have identified a molecular pathway that when silenced could restore the normal function of immune cells in people with fatty liver disease.

Longevity protein SIRT6 also protects against fatty liver and fatty liver disease
SIRT6 regulates fat metabolism by activating another protein called peroxisome proliferator-activated receptor alpha (PPAR-alpha).

Fresh insights could lead to new treatments for liver disease
The fight against liver disease could be helped by the discovery of cells that cause liver scarring.

Better methods needed for predicting risk of liver disease
While blood samples can reliably identify people with a low risk of developing severe liver disease, better methods are needed in primary care for identifying people in most need of care.

Lab-on-a-chip may help identify new treatments for liver disease
Investigators have developed a 'lab on a chip' technology that can simulate different levels of non-alcoholic fatty liver disease progression.

Read More: Liver Disease News and Liver Disease Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.